Linked Life Data

15605667

Source:http://linkedlifedata.com/resource/pubmed/id/15605667

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15605667rdf:typepubmed:Citationlld:pubmed
pubmed-article:15605667lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:15605667lifeskim:mentionsumls-concept:C0003873lld:lifeskim
pubmed-article:15605667lifeskim:mentionsumls-concept:C0036043lld:lifeskim
pubmed-article:15605667lifeskim:mentionsumls-concept:C1176415lld:lifeskim
pubmed-article:15605667pubmed:issue11lld:pubmed
pubmed-article:15605667pubmed:dateCreated2004-12-20lld:pubmed
pubmed-article:15605667pubmed:abstractTextA randomised, double-blind study was performed to assess the efficacy and tolerability of lumiracoxib in patients with rheumatoid arthritis (RA). Patients received lumiracoxib 200mg once daily (o.d.) (n= 280), lumiracoxib 400mg o.d. (n= 281), naproxen 500 mg twice daily (n= 279) or placebo (n= 284) for 26 weeks. The primary efficacy variable was response to treatment according to ACR20 criteria (adjusted for prohibited concomitant or excessive rescue medication use and discontinuations due to unsatisfactory therapeutic response) at week 13. Safety and tolerability was also assessed. Significantly more patients receiving lumiracoxib than placebo were responders according to ACR20 criteria at week 13 (41.1 and 42.7% for lumiracoxib 200 and 400 mg o.d., respectively; 32.4% for placebo; both p < 0.05). The proportion responding to naproxen (39.1%) was not significantly different from placebo. Prespecified gastrointestinal adverse events were more frequent with naproxen than with either lumiracoxib dose or placebo. Lumiracoxib is therefore an effective and well-tolerated therapy for RA.lld:pubmed
pubmed-article:15605667pubmed:languageenglld:pubmed
pubmed-article:15605667pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15605667pubmed:citationSubsetIMlld:pubmed
pubmed-article:15605667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15605667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15605667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15605667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15605667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15605667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15605667pubmed:statusMEDLINElld:pubmed
pubmed-article:15605667pubmed:monthNovlld:pubmed
pubmed-article:15605667pubmed:issn1368-5031lld:pubmed
pubmed-article:15605667pubmed:authorpubmed-author:RichardsonPPlld:pubmed
pubmed-article:15605667pubmed:authorpubmed-author:GeusensPPlld:pubmed
pubmed-article:15605667pubmed:authorpubmed-author:AlteaEElld:pubmed
pubmed-article:15605667pubmed:authorpubmed-author:SloanV SVSlld:pubmed
pubmed-article:15605667pubmed:authorpubmed-author:RovenskyJJlld:pubmed
pubmed-article:15605667pubmed:authorpubmed-author:KrammerGGlld:pubmed
pubmed-article:15605667pubmed:authorpubmed-author:KralidisGGlld:pubmed
pubmed-article:15605667pubmed:issnTypePrintlld:pubmed
pubmed-article:15605667pubmed:volume58lld:pubmed
pubmed-article:15605667pubmed:ownerNLMlld:pubmed
pubmed-article:15605667pubmed:authorsCompleteYlld:pubmed
pubmed-article:15605667pubmed:pagination1033-41lld:pubmed
pubmed-article:15605667pubmed:dateRevised2009-11-6lld:pubmed
pubmed-article:15605667pubmed:meshHeadingpubmed-meshheading:15605667...lld:pubmed
pubmed-article:15605667pubmed:meshHeadingpubmed-meshheading:15605667...lld:pubmed
pubmed-article:15605667pubmed:meshHeadingpubmed-meshheading:15605667...lld:pubmed
pubmed-article:15605667pubmed:meshHeadingpubmed-meshheading:15605667...lld:pubmed
pubmed-article:15605667pubmed:meshHeadingpubmed-meshheading:15605667...lld:pubmed
pubmed-article:15605667pubmed:meshHeadingpubmed-meshheading:15605667...lld:pubmed
pubmed-article:15605667pubmed:meshHeadingpubmed-meshheading:15605667...lld:pubmed
pubmed-article:15605667pubmed:meshHeadingpubmed-meshheading:15605667...lld:pubmed
pubmed-article:15605667pubmed:meshHeadingpubmed-meshheading:15605667...lld:pubmed
pubmed-article:15605667pubmed:meshHeadingpubmed-meshheading:15605667...lld:pubmed
pubmed-article:15605667pubmed:meshHeadingpubmed-meshheading:15605667...lld:pubmed
pubmed-article:15605667pubmed:meshHeadingpubmed-meshheading:15605667...lld:pubmed
pubmed-article:15605667pubmed:meshHeadingpubmed-meshheading:15605667...lld:pubmed
pubmed-article:15605667pubmed:meshHeadingpubmed-meshheading:15605667...lld:pubmed
pubmed-article:15605667pubmed:meshHeadingpubmed-meshheading:15605667...lld:pubmed
pubmed-article:15605667pubmed:meshHeadingpubmed-meshheading:15605667...lld:pubmed
pubmed-article:15605667pubmed:year2004lld:pubmed
pubmed-article:15605667pubmed:articleTitleEfficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis.lld:pubmed
pubmed-article:15605667pubmed:affiliationBiomedisch Onderzoeksinstituut, Limburgs Universitair Centrum, Diepenbeek, Belgium. piet.geusens@ping.belld:pubmed
pubmed-article:15605667pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15605667pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:15605667pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:15605667pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:15605667pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:15605667pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15605667lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15605667lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15605667lld:pubmed